Skip to main content

Dose Attenuated Chemotherapy in Compromised Patients with Lung Cancer - Clinical Trial

Study Summary

“Julia Judd, MD

The purpose of this research study is to determine whether specific, planned adjustments to the doses of the drugs before your patient receives the first dose will make receiving treatment easier (that is to say, fewer side effects) while keeping the same level of effectiveness against the cancer.

If the screening procedures show your patient can take part in the study and they decide to take part in the study, they will receive the treatment drug you prescribe, with the specific change in dose or frequency that it is administered, determined by the study.

Approximately 280 people will take part in this research study.

Your patient will be asked to take the study drugs as long as they are benefitting from the treatment or their disease does not get worse. Your patient will be removed from the study if you think that they have unacceptable toxicities due to the study drug/s and it is in their best interest that they stop participating in the study.

We will perform a safety follow-up 30 days after the end of treatment visit. We will follow up with your patient every 3 months by phone call for up to 5 years.

Contact Us
About This Trial:

For more information about this and other studies and to inquire about eligibility, please call 215-214-1515. or fill out this form.

Protocol:
22-1052 / IRB22-1052

Phase:
II

Investigator:
Julia Judd, DO

Disease(s):
Lung

ClinicalTrials.gov
Visit ClinicalTrials.gov for a full clinical trial description

Full Title

TH-214: Phase II Study of Dose Attenuated Chemotherapy in Patients with Lung Cancer and Age > 70 and/or Comorbidities

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

    Must have histologically or cytologically confirmed stage IV (AJCC version 8) lung cancer (small cell or non-small cell). Patients with stage III disease who are not felt to be candidates for definitive therapy are also eligible.
    Must fit into at least one of the subgroups of patients as defined in section 3.3.
      Patients must have planned therapy with a regimen that includes at least one cytotoxic agent as listed in Table 1 (e.g. platinum, taxane, anti-metabolite, vinca alkaloid, podophyllotoxin, camptothecin, lurbinectedin etc.).

For more information about this and other studies and to inquire about eligibility, please call 215-214-1515.